Rheumatoid Arthritis

Treatment approaches for the management of secondary HLH is problematic due to the heterogeneity of approaches and rarity of the condition.

Managing CTDs may have an overall benefit on cardiovascular health.

This is the first time such an algorithm was validated in a large US claims database.

Gilead expects topline results available from a pair of trials testing the new treatment in 2021.

It is important for clinicians considering prescribing denosumab treatment to counsel patients before its initiation on the importance of not delaying or discontinuing injections.

Findings of the trial on tocilizumab fall short.

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.

The incidence rate of serious infection events and opportunistic infections was higher among the upadacitinib 30 mg group than the 15 mg group.

In a late-breaking abstract, investigators test nanoparticle treatment using in vivo models.

In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.

The findings are important to understand treatment persistence and switch patterns in rheumatoid arthritis patients with poor prognostic factors in a real-world setting.

The results highlight a significant improvement in rheumatoid arthritis signs and symptoms for those who used upadacitinib over placebo and adalimumab.

In a study presented at EULAR, investigators find 14-3-3η baseline levels did not correlate with baseline mTSS.

Patients are unaffected by the switch from ADL-EU to ADL-PF.

Medical director of Horizon Therapeutics discusses changes in rheumatology practices as a result of the ongoing pandemic.

A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.